Regenerative neuroscience is redefining what is possible in the treatment of neurodegenerative disease. For decades, Alzheimer's disease, Parkinson's disease, and age-related cognitive decline have resisted pharmacological intervention because available treatments address downstream symptoms rather than the upstream biology of neuronal loss. The emergence of small molecule neurogenesis activators, endogenous neural stem cell stimulation, and blood-brain barrier-permeable compounds represents a fundamental shift in therapeutic strategy. This course positions clinicians at that frontier.

Presented by Dr. Kiminobu Sugaya, PhD, Professor and Head of Neuroscience at the University of Central Florida College of Medicine, this one-hour continuing education course explores the science behind APC-100, a compound that combines KS217, a neural stem cell proliferation activator, and Fenselin, an amyloid precursor protein expression reducer. Together, this dual-mechanism approach has demonstrated up to a 600 percent increase in endogenous neural stem cell activity and full restoration of spatial memory in five-gene familial Alzheimer's disease transgenic mouse models. No surgery. No cell preparation. Oral administration only.

This course is designed for licensed healthcare clinicians working at the intersection of neurology, functional medicine, rehabilitation, and human performance who want to understand where regenerative science is heading and why the mechanisms driving it matter for clinical decision-making today. Whether you manage patients with early cognitive decline, advise on neuroprotective strategies, or simply want to understand the science your field is moving toward, this course delivers substantive, research-grounded insight from a researcher who has spent decades building it.

Dr. Sugaya's laboratory at UCF has pioneered techniques for reprogramming mesenchymal stem cells toward neural lineages, developing salivary biomarkers for brain staging, and advancing translational research funded by the NIH, the Alzheimer's Association, and the Florida Department of Health. His work challenges the amyloid hypothesis not from the margins but from a position of published, peer-reviewed evidence spanning more than two decades. This course reflects that depth.